Literature DB >> 22955274

Interleukin-10 inhibits lipopolysaccharide-induced tumor necrosis factor-α translation through a SHIP1-dependent pathway.

Catherine S Chan1, Andrew Ming-Lum, Gary B Golds, Shaina J Lee, Raymond J Anderson, Alice L-F Mui.   

Abstract

Production of the proinflammatory cytokine TNFα by activated macrophages is an important component of host defense. However, TNFα production must be tightly controlled to avoid pathological consequences. The anti-inflammatory cytokine IL-10 inhibits TNFα mRNA expression through activation of the STAT3 transcription factor pathway and subsequent expression of STAT3-dependent gene products. We hypothesized that IL-10 must also have more rapid mechanisms of action and show that IL-10 rapidly shifts existing TNFα mRNA from polyribosome-associated polysomes to monosomes. This translation suppression requires the presence of SHIP1 (SH2 domain-containing inositol 5'-phosphatase 1) and involves inhibition of Mnk1 (MAPK signal-integrating kinase 1). Furthermore, activating SHIP1 using a small-molecule agonist mimics the inhibitory effect of IL-10 on Mnk1 phosphorylation and TNFα translation. Our data support the existence of an alternative STAT3-independent pathway through SHIP1 for IL-10 to regulate TNFα translation during the anti-inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22955274      PMCID: PMC3488072          DOI: 10.1074/jbc.M112.348599

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Mnk earmarks eIF4E for cancer therapy.

Authors:  Nissim Hay
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

2.  Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells.

Authors:  Christopher J Ong; Andrew Ming-Lum; Matt Nodwell; Ali Ghanipour; Lu Yang; David E Williams; Joseph Kim; Loutfig Demirjian; Pooran Qasimi; Jens Ruschmann; Li-Ping Cao; Kewei Ma; Stephen W Chung; Vincent Duronio; Raymond J Andersen; Gerald Krystal; Alice L-F Mui
Journal:  Blood       Date:  2007-05-14       Impact factor: 22.113

Review 3.  Posttranscriptional regulation of TNF mRNA: a paradigm of signal-dependent mRNA utilization and its relevance to pathology.

Authors:  Panagiota Stamou; Dimitris L Kontoyiannis
Journal:  Curr Dir Autoimmun       Date:  2010-02-18

Review 4.  MAPKAP kinases MK2 and MK3 in inflammation: complex regulation of TNF biosynthesis via expression and phosphorylation of tristetraprolin.

Authors:  Natalia Ronkina; Manoj B Menon; Jessica Schwermann; Christopher Tiedje; Edward Hitti; Alexey Kotlyarov; Matthias Gaestel
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

5.  Cutting edge: A transcriptional repressor and corepressor induced by the STAT3-regulated anti-inflammatory signaling pathway.

Authors:  Karim C El Kasmi; Amber M Smith; Lynn Williams; Geoffrey Neale; Athanasia D Panopoulos; Athanasia Panopolous; Stephanie S Watowich; Hans Häcker; Brian M J Foxwell; Peter J Murray
Journal:  J Immunol       Date:  2007-12-01       Impact factor: 5.422

6.  Interleukin-1 receptor-associated kinase 2 is critical for lipopolysaccharide-mediated post-transcriptional control.

Authors:  Youzhong Wan; Hui Xiao; Jeremy Affolter; Tae Whan Kim; Katarzyna Bulek; Sujan Chaudhuri; Deborah Carlson; Thomas Hamilton; Barsanjit Mazumder; George R Stark; James Thomas; Xiaoxia Li
Journal:  J Biol Chem       Date:  2009-02-18       Impact factor: 5.157

Review 7.  The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases).

Authors:  Maria Buxade; Josep L Parra-Palau; Christopher G Proud
Journal:  Front Biosci       Date:  2008-05-01

8.  Inhibition of tristetraprolin deadenylation by poly(A) binding protein.

Authors:  Robert M Rowlett; Carol A Chrestensen; Melanie J Schroeder; Mary G Harp; Jared W Pelo; Jeffery Shabanowitz; Robert DeRose; Donald F Hunt; Thomas W Sturgill; Mark T Worthington
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-05-08       Impact factor: 4.052

9.  Tristetraprolin is required for full anti-inflammatory response of murine macrophages to IL-10.

Authors:  Barbara Schaljo; Franz Kratochvill; Nina Gratz; Iwona Sadzak; Ines Sauer; Michael Hammer; Claus Vogl; Birgit Strobl; Mathias Müller; Perry J Blackshear; Valeria Poli; Roland Lang; Peter J Murray; Pavel Kovarik
Journal:  J Immunol       Date:  2009-06-19       Impact factor: 5.422

10.  Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility.

Authors:  Andre Franke; Tobias Balschun; Tom H Karlsen; Jurgita Sventoraityte; Susanna Nikolaus; Gabriele Mayr; Francisco S Domingues; Mario Albrecht; Michael Nothnagel; David Ellinghaus; Christian Sina; Clive M Onnie; Rinse K Weersma; Pieter C F Stokkers; Cisca Wijmenga; Maria Gazouli; David Strachan; Wendy L McArdle; Séverine Vermeire; Paul Rutgeerts; Philip Rosenstiel; Michael Krawczak; Morten H Vatn; Christopher G Mathew; Stefan Schreiber
Journal:  Nat Genet       Date:  2008-10-05       Impact factor: 38.330

View more
  17 in total

1.  Pentoxifylline inhibits pulmonary inflammation induced by infrarenal aorticcross-clamping dependent of adenosine receptor A2A.

Authors:  Hali Li; Gang Tan; Liquan Tong; Peng Han; Feng Zhang; Bing Liu; Xueying Sun
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

2.  IL-10-Induced miR-155 Targets SOCS1 To Enhance IgE-Mediated Mast Cell Function.

Authors:  Amina Abdul Qayum; Anuya Paranjape; Daniel Abebayehu; Elizabeth Motunrayo Kolawole; Tamara T Haque; Jamie Josephine Avila McLeod; Andrew J Spence; Heather L Caslin; Marcela T Taruselli; Alena P Chumanevich; Bianca Baker; Carole A Oskeritzian; John J Ryan
Journal:  J Immunol       Date:  2016-04-29       Impact factor: 5.422

Review 3.  STAT3 signaling in immunity.

Authors:  Emily J Hillmer; Huiyuan Zhang; Haiyan S Li; Stephanie S Watowich
Journal:  Cytokine Growth Factor Rev       Date:  2016-05-09       Impact factor: 7.638

Review 4.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

Review 5.  Regulator Versus Effector Paradigm: Interleukin-10 as Indicator of the Switching Response.

Authors:  Ervin Ç Mingomataj; Alketa H Bakiri
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

6.  Interleukin-10 inhibits lipopolysaccharide induced miR-155 precursor stability and maturation.

Authors:  Sylvia T Cheung; Eva Y So; David Chang; Andrew Ming-Lum; Alice L-F Mui
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

7.  Elevated Interleukin-10 Levels in COVID-19: Potentiation of Pro-Inflammatory Responses or Impaired Anti-Inflammatory Action?

Authors:  Hashim Islam; Thomas C Chamberlain; Alice L Mui; Jonathan P Little
Journal:  Front Immunol       Date:  2021-06-21       Impact factor: 7.561

8.  Mathematical Model of Innate and Adaptive Immunity of Sepsis: A Modeling and Simulation Study of Infectious Disease.

Authors:  Zhenzhen Shi; Chih-Hang J Wu; David Ben-Arieh; Steven Q Simpson
Journal:  Biomed Res Int       Date:  2015-09-08       Impact factor: 3.411

Review 9.  The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges.

Authors:  Andrew P Hutchins; Diego Diez; Diego Miranda-Saavedra
Journal:  Brief Funct Genomics       Date:  2013-08-12       Impact factor: 4.241

10.  Hyporesponsiveness to the anti-inflammatory action of interleukin-10 in type 2 diabetes.

Authors:  Julianne C Barry; Soroush Shakibakho; Cody Durrer; Svetlana Simtchouk; Kamaldeep K Jawanda; Sylvia T Cheung; Alice L Mui; Jonathan P Little
Journal:  Sci Rep       Date:  2016-02-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.